Literature DB >> 24613269

Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.

Khairuddin Memon1, Laura M Kulik2, Robert J Lewandowski1, Edward Wang3, Jonathan Wang1, Robert K Ryu1, Ryan Hickey1, Michael Vouche1, Talia Baker3, Daniel Ganger2, Vanessa L Gates1, Ali Habib1, Mary F Mulcahy4, Riad Salem5.   

Abstract

PURPOSE: To compare the utility of different staging systems and analyze independent predictors of survival in patients with hepatocellular carcinoma (HCC) treated with yttrium-90 ((90)Y) radioembolization.
MATERIALS AND METHODS: During the period 2004-2011, 428 patients with HCC were treated with (90)Y radioembolization. All patients were staged prospectively by the following staging systems: Child-Turcotte-Pugh (CTP), United Network for Organ Sharing, Barcelona Clinic Liver Cancer (BCLC), Okuda classification, Cancer of the Liver Italian Program (CLIP), Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire, Chinese University Prognostic Index, and Japan Integrated Staging. The ability of the staging systems to predict survival was assessed. The staging systems were compared using Cox proportional hazards regression model, linear regression, Akaike information criterion (AIC), and concordance index (C-index). Univariate and multivariate analyses were employed to assess independent predictors of survival.
RESULTS: When tested independently, all staging systems exhibited significant ability to discriminate early (long survival) from advanced (worse survival) disease. CLIP provided the most accurate information in predicting survival outcomes (AIC = 2,993, C-index = 0.8503); CTP was least informative (AIC = 3,074, C-index = 0.6445). Independent predictors of survival included Eastern Cooperative Oncology Group performance status grade 0 (hazard ration [HR], 0.56; confidence interval [CI], 0.34-0.93), noninfiltrative tumors (HR, 0.62; CI, 0.44-0.89), absence of portal venous thrombosis (HR, 0.60; CI, 0.40-0.89), absence of ascites (HR, 0.56; CI, 0.40-0.76), albumin ≥ 2.8 g/dL (HR, 0.72; CI, 0.55-0.94), alkaline phosphatase ≤ 200 U/L (HR, 0.68; CI, 0.50-0.92), and α-fetoprotein ≤ 200 ng/mL (HR, 0.67; CI, 0.51-0.86).
CONCLUSIONS: CLIP was most accurate in predicting survival in patients with HCC. Given that not all patients receive the recommended BCLC treatment strategy, this information is relevant for clinical trial design and predicting long-term outcomes after (90)Y radioembolization.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24613269      PMCID: PMC5097871          DOI: 10.1016/j.jvir.2014.01.010

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  38 in total

1.  Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.

Authors:  Philip Hilgard; Monia Hamami; Amr El Fouly; André Scherag; Stefan Müller; Judith Ertle; Till Heusner; Vito R Cicinnati; Andreas Paul; Andreas Bockisch; Guido Gerken; Gerald Antoch
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

2.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

Review 3.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma: molecular biology and therapy.

Authors:  Ghassan K Abou-Alfa
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

Review 6.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

7.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

8.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto.

Authors:  I Levy; M Sherman
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

9.  Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.

Authors:  Daniel B Brown; Christopher E Fundakowski; Mauricio Lisker-Melman; Jeffrey S Crippin; Thomas K Pilgram; William Chapman; Michael D Darcy
Journal:  J Vasc Interv Radiol       Date:  2004-11       Impact factor: 3.464

10.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

View more
  10 in total

1.  Validation of a Liver Index and Its Significance for HCC Aggressiveness.

Authors:  Brian I Carr; Vito Guerra
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.

Authors:  Jae Ho Sohn; Rafael Duran; Yan Zhao; Florian Fleckenstein; Julius Chapiro; Sonia Sahu; Rüdiger E Schernthaner; Tianchen Qian; Howard Lee; Li Zhao; James Hamilton; Constantine Frangakis; MingDe Lin; Riad Salem; Jean-Francois Geschwind
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-12       Impact factor: 11.382

4.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

5.  Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma.

Authors:  Brian I Carr; Vito Guerra; Rossella Donghia; Seai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-10-06

6.  Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features.

Authors:  Wenlong Song; Qianyu Chen; Dajing Guo; Caiming Jiang
Journal:  Radiol Med       Date:  2022-08-26       Impact factor: 6.313

7.  Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Authors:  Matthew Walton; Ros Wade; Lindsay Claxton; Sahar Sharif-Hurst; Melissa Harden; Jai Patel; Ian Rowe; Robert Hodgson; Alison Eastwood
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

8.  A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Alberto Masotto; Franco Trevisani
Journal:  J Integr Oncol       Date:  2016-09-05

9.  Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.

Authors:  Ece Meram; Colin Longhurst; Baran Umut Vardar; Kerim Karaoglu; Paul F Laeseke; Orhan S Ozkan
Journal:  Heliyon       Date:  2022-01-13

10.  The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: A meta-analysis.

Authors:  Ping Sun; Shihai Chen; Yanlong Li
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.